NTRK fusion solid tumours
Oncology · 2021–2022
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| larotrectinib Locally advanced or metastatic solid tumours harbouring NTRK gene fusions that are unresectable locally advanced, metastatic, or locally advanced and would… | Mar 2022 | Deferred | input received Medical Oncology Group |
| larotrectinib Locally advanced or metastatic solid tumours harbouring NTRK gene fusion that are unresectable locally advanced, metastatic, or locally advanced and would… | Nov 2021 | Deferred | input received Medical Oncology Group |
Who spoke
Medical Oncology Group
What the PBS pays
$2M in government benefit over 2024–25, across 271 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| larotrectinib | $2.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.